Back to top
more

SiBone (SIBN)

(Delayed Data from NSDQ)

$14.48 USD

14.48
628,451

+0.28 (1.97%)

Updated May 6, 2024 04:00 PM ET

After-Market: $13.65 -0.83 (-5.73%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Is a Beat Likely for Intuitive Surgical (ISRG) in Q4 Earnings?

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

Hologic (HOLX) Q1 Earnings Might Rise on Breast Health Growth

Strong performance in the Breast Health segment is likely to boost Hologic's (HOLX) Q1 result.

Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?

Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.

Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?

Strength in Breast Health and GYN Surgical businesses are likely to contribute to Hologic's (HOLX) Q1 2024 revenues.

What's in Store for Boston Scientific (BSX) in Q4 Earnings?

Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

Align Technology's (ALGN) fourth-quarter 2023 results are likely to reflect the strength of the Clear Aligner and Systems & Services businesses.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.

What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?

Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.

Si-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for Investors

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

Si-Bone (SIBN) Upgraded to Buy: Here's Why

Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Walgreens (WBA) New Study Shows Medical Adherence Importance

Walgreens' (WBA) latest research findings highlight the importance of patients adhering to their therapy.

Hologic (HOLX) Gains From New Launches as Macro Concerns Rise

Hologic (HOLX) has been making impressive progress in its Breast Health arm, leveraging its strategic expansion efforts to diversify business across the patient continuum of care.

Abbott (ABT) Broadens Electrophysiology Footprint With TactiFlex

The successful deployment of Abbott's (ABT) TactiFlex Ablation Catheter, Sensor Enabled in Canada broadens the company's global footprint in the electrophysiology space.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.

Abbott (ABT) Unveils Connected Diabetes App With New Pact

Abbott's (ABT) FreeStyle Libre portfolio is the world's top sensor-based CGM system, changing the lives of over 5 million people.

Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities

Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.

Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now

Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.

Phibro (PAHC) Sales Impacted by Macro Concerns, FX Headwind

The COVID-19 pandemic has adversely affected the international economic conditions and financial markets, leading to an economic downturn in many countries, in which Phibro (PAHC) operates.

Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform

Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and stable liquidity.

Teleflex (TFX) Rides on Urolift Prospects Amid Cost Pressures

With respect to Teleflex's (TFX) market development objectives for UroLift, the company witnesses growth for UroLift in the hospital setting.

Teleflex (TFX) Picked for Vizient Innovative Technology Exchange

Teleflex (TFX) gets selected to exhibit Arrow VPS Rhythm DLX Device and Arrow PICCs preloaded with the NaviCurve Stylet at the Vizient Innovative Technology Exchange.

Alcon (ALC) Gains From Innovation & International Expansion

Alcon's (ALC) Surgical business continues to gain from diverse portfolio and incremental innovation.

Teleflex (TFX) New Survey Highlights BPH Impact Life Quality

Teleflex's (TFX) survey results highlight how crucial it is for men to consult a urologist if they have strange or troublesome urine symptoms.